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We conducted a case control study of selective cyclooxygenase-2 (COX-2) blocking agents and lung cancer. A 
total of 492 newly diagnosed lung cancer cases were ascertained during January 1, 2002 to September 30, 2004, at 
The Ohio State University Medical Center, Columbus, Ohio. All cases were confirmed by examination of the 
pathology report. Healthy population controls without cancer were ascertained during the same time period. 
Controls were frequency matched at a rate of 2:1 to the cases by age, gender, and county of residence. We col-
lected information on type, frequency, and duration of use of selective COX-2 inhibitors (primarily celecoxib or 
rofecoxib) and nonselective NSAIDs such as ibuprofen and aspirin. Estimates of odds ratios (OR) were obtained 
with adjustment for cigarette smoking, age and other potential confounders using logistic regression analysis. 
Odds Ratios for selective COX-2 inhibitors were adjusted for past use of other NSAIDs. Use of any selective 
COX-2 inhibitor for more than one year produced a significant (60%) reduction in the risk of lung cancer 
(OR=0.40, 95% CI=0.19-0.81). Observed risk reductions were consistent for men (OR=0.26, 95% CI=0.10-0.62) and 
women (OR=0.52, 95% CI=0.24-1.13) and for individual COX-2 inhibitors (OR=0.28, 95% CI=-0.12-0.67, for cele-
coxib and OR=0.55, 95% CI=0.19-1.56, for rofecoxib). Intake of ibuprofen or aspirin also produced significant risk 
reductions (OR=0.40, 95% CI=0.23-0.73 and OR=0.53, 95% CI=0.34-0.82, respectively), whereas acetaminophen, 
an analgesic with negligible COX-2 activity, had no effect on the risk (OR=1.36, 95% CI=0.53-3.37). This investi-
gation demonstrates for the first time that selective COX-2 blocking agents have strong potential for the chemo-
prevention of human lung cancer.  
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1.  INTRODUCTION 
The American Cancer Society estimates that more 
than 1.4 million new cases of invasive cancer will be 
diagnosed during 2006 in the United States, and more 
than 564,000 Americans will die from cancer [1]. When 
age-adjusted death rates are considered, cancer has 
surpassed heart disease and is now the leading cause 
of death among American women and men under age 
85. The majority (about 60%) of cancer deaths are at-
tributable to four major cancer types: lung, breast, 
prostate, and colon. Lung cancer is by far the leading 
cause of cancer death in both men and women, causing 
nearly 93,000 deaths in men and 82,000 deaths in 
women every year. The number of deaths due to lung 
cancer exceeds that of breast cancer, prostate cancer, 
and colon cancer combined. Despite intensive efforts 
aimed primarily at early detection and therapy of lung 
cancer, its high mortality rates have persisted for sev-
eral decades. Innovative research efforts must there-
fore be redirected towards chemoprevention of the 
early stages of lung carcinogenesis. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) and 
cancer  
The epidemiologic literature provides consistent 
evidence that regular intake of NSAIDs with 
non-selective activity against cyclooxygenase-2 
(COX-2) protects against the development of many 
types of neoplasms including lung cancer [2, 3, 4)] 
Notably, a recent case control study documented sig-
nificant effects of selective COX-2 inhibitors (celecoxib 
and rofecoxib) against breast cancer [5] Nevertheless, 
there are currently no other published studies of selec-
tive COX-2 inhibitors and cancer.  
Lung Cancer and NSAIDs  
The early preclinical studies of Schuller et al. [6] 
and Castonguay and Rioux [7, 8] provide convincing 
evidence that inhibition of prostaglandin biosynthesis 
by various NSAIDs reduces the development of 
chemically induced pulmonary adenocarcinoma. Wolf 
et al. [9], Hida et al. [10], Koki et al. [11], and other in-
vestigators have observed that COX-2 is 
over-expressed in 70-90% of human pulmonary ade-
nocarcinomas and other non-small cell lung cancers. 
Additional molecular studies by Schuller and col-
leagues [12, 13, 14, 15] determined that lung carcino-
genesis is linked to the stimulation of beta-adrenergic 
receptors by nitrosamines and possibly other tobacco 
carcinogens. They have identified a novel mechanism 
by which the nitrosamine, NNK, modulates the ara-Int. J. Biol. Sci. 2007, 3 
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chidonic acid cascade and DNA synthesis through 
signal transduction involving both beta-1 and beta-2 
adrenergic receptors. Notably, this effect is inhibited 
by administration of NSAIDs [12]. 
Early prospective epidemiologic investigations 
by Peto et al. [16] and Schreinemachers and Everson 
[17] suggested that regular aspirin intake produced a 
significant reduction in lung cancer risk. Subsequently, 
other investigators have also observed protective ef-
fects of aspirin and other NSAIDs against the devel-
opment of lung cancer [18, 19] and a recent 
meta-analysis of eleven published epidemiologic 
studies found that regular intake of NSAIDs produced 
a 36% reduction in the risk of lung cancer [3]. 
In one case control study designed to specifically 
compare the use of NSAIDs between smokers who 
developed lung cancer (smoking cases) and control 
subjects who also smoked, regular intake of NSAIDs 
with non-selective COX-2 activity (primarily aspirin 
and ibuprofen) produced a 69% reduction in the rela-
tive risk of lung cancer [18]. In contrast, acetamino-
phen, a comparator analgesic without COX-2 activity, 
had no effect on the risk of lung cancer. These findings 
clearly suggest that COX-2 blockade inhibits lung car-
cinogenesis among smokers.  
Rationale for epidemiologic investigation of selective 
COX-2 inhibitors  
Taken together, the above results provide the 
background and significance to conduct further epi-
demiologic studies to examine the chemopreventive 
potential of selective COX-2 blockade against lung 
cancer and other forms of malignancy. Significant use 
of selective cyclooxygenase-2 (COX-2) blocking agents 
such as celecoxib (Celebrex) and rofecoxib (Vioxx) 
prescribed for the treatment of arthritis during 1999 to 
September 30, 2004 (the date of the recall of Vioxx from 
the worldwide marketplace by its manufacturer, 
Merck) facilitates epidemiologic investigations to il-
luminate their chemopreventive effects against major 
cancers.  
We therefore designed a case control investiga-
tion to estimate and test odds ratios as measures of 
preventive effects of selective COX-2 agents against 
lung cancer, the deadliest of all malignancies. Specifi-
cally, we examined the chemopreventive effects of 
selective COX-2 inhibitors (celecoxib, valdecoxib, ro-
fecoxib, and meloxicam) against invasive lung cancer 
utilizing a case control epidemiological design. Effects 
of COX-2 blockade were quantified in comparisons of 
cancer cases with healthy controls. This investigation 
was designed to collect initial critical evidence on the 
relative potential of selective COX-2 blocking agents in 
the chemoprevention of cancers of the lung. 
2.  RESEARCH DESIGN AND METHODS 
Experimental design and population studied  
The experimental design is a retrospective case 
control study of lung cancer with frequency matching 
of cases and control subjects for age, gender, and loca-
tion of residence. We studied 492 cases of invasive 
lung cancer with histological verification based upon 
review of the pathology records, and cancer-free con-
trols frequency matched to the cases at a 2:1 ratio. 
Among the case series, 84% had non-small cell lung 
cancers (43% adenocarcinomas, 35% squamous cell 
carcinomas and 6% large cell carcinomas), 11% had 
small cell carcinomas, and 6% had other histologic cell 
types. We utilized the mammography screening ser-
vice and the prostate screening service for ascertain-
ment of healthy female and male control subjects, re-
spectively, without cancer. The 984 controls were as-
certained with frequency matching to the cases at a 
rate of 2:1 on age, gender, race, and place (county) of 
residence. The protocol was approved by the Internal 
Review Board of The Ohio State University Medical 
Center.  
Data collection  
Critical information on exposure to selective 
COX-2 inhibitors, non-selective NSAIDs, and other 
factors was obtained by trained medical personnel at 
the time of cancer diagnosis for cases or screening visit 
for controls. We collected accurate and comprehensive 
information on the type, frequency of use, dose, and 
duration of use of both prescription and 
non-prescription drugs. Other data variables collected 
consisted of demographic characteristics, height, 
weight, menstrual and pregnancy history for women, 
family history of cancer, comprehensive information 
on cigarette smoking, alcohol intake, pre-existing 
medical conditions (arthritis, chronic headache, car-
diovascular conditions including hypertension, angina, 
ischemic attacks, stroke, and myocardial infarction, 
lung disease, and diabetes mellitus), and medication 
history including over the counter and prescription 
NSAIDs, and exogenous hormones. Regarding selec-
tive COX-2 inhibitors and other NSAIDs, the use pat-
tern (frequency, dose, and duration), the type, such as 
celecoxib, valdecoxib, rofecoxib, meloxicam, aspirin, 
ibuprofen, naproxen, indomethacin, etc, were recorded. 
Data on the related analgesic, acetaminophen were 
collected for comparison with selective COX-2 inhibi-
tors and other NSAIDs.  
Biostatistical analysis  
Effects of the selective COX-2 inhibitors as a 
group were quantified by estimating odds ratios and 
their 95% confidence intervals. Odds ratios were ad-
justed for age and other factors by logistic regression 
analysis [20, 21, 22]. In addition, odds ratios for COX-2 
inhibitors were adjusted for past years of use of other 
types of NSAIDs (aspirin, ibuprofen, or naproxen). 
Data were stratified by gender, ethnicity, and by can-
cer risk factors (e.g., smokers and non-smokers) and 
odds ratios estimated within subgroups and checked 
(by chi square tests) for internal consistency, effect 
modification, and confounding. Adjusted estimates 
were obtained for specific types of compounds, e.g, 
celecoxib and rofecoxib. Similar methods were applied 
for the non-selective NSAIDs, regular (325 mg) aspirin 
and ibuprofen, low dose (81 mg) aspirin, and the an-
algesic, acetaminophen.  Int. J. Biol. Sci. 2007, 3 
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3.  RESULTS 
Pertinent characteristics of the cases and controls 
are given in Table 1. As expected, cases and controls 
had similar distributions of gender, age, race, and 
education, whereas the cases exhibited a marked ex-
cess of chronic cigarette smoking. The strong etiologic 
association of lung cancer with chronic smoking is 
reflected by the increasing dose response in the odds 
ratio with greater pack years of exposure (OR=17.3, 
95% CI=10.8-27.6 for 1-19 pack years and OR=52.4, 
95% CI=34.8-71.9 for 20 or more pack years). The cases 
also reported a slightly higher frequency of upper res-
piratory cancers among first and second degree rela-
tives, and a reduction in body mass index at the time of 
diagnosis. 
Table 1. Characteristics of lung cancer cases and controls. 
Characteristic a Cases  (N=492)  Controls  (N=984) 
Gender (female)    40.4% 40.3% 
Age (yrs)    
 <50  12%  13% 
 50-65  35  34 
 >65  53  53 
  Mean (SEM)  64.4 ( 0.5)  64.1 ( 0.5) 
Race      
  Caucasian  87 %  89 % 
 All  Other  13  11 
Education      
  ≤ 12 yrs  91 %  88 % 
 >  12  yrs   9  12  
Family History      
  Positive  17 %  12 %   
 Negative  83  88  (p<0.05) 
Body Mass (BMI)    
 BMI  ≤ 22  14 %  6 % 
 BMI  22-25  53  37 
 BMI  26-29  19  28 
 BMI  ≥ 30  13  29 (p<0.01) 
  Mean (SEM)  25.7 ( 0.9)  28.3 ( 0.7)   
Chronic Smoking    
 None   6  %  72  %  
 1-19  pack-years  17  12 
  ≥ 20 pack-years  77  16 (p<.0001) 
Alcohol Intake    
  None  52 %  47 % 
  1-2 drinks per 
week 
26 25 
  > 2 drinks per 
week 
22 28 
a Family History: lung cancer or other upper respiratory cancer among 
first or second degree relatives; Body Mass Index = weight (kg) / ht 2 (m). 
 
Risk estimates (odds ratios) for selective COX-2 
inhibiting agents and other types of NSAIDs are pre-
sented in Table 2. It is important to note that all esti-
mates are adjusted for a measure of the predominant 
risk factor for lung cancer, pack years of cigarette 
smoking. Furthermore, the odds ratios for COX-2 in-
hibitors are adjusted for past years of use of nonselec-
tive NSAIDs. The duration of exposure was up to 7 
years for COX-2 inhibitors and more than 10 years for 
the non-selective NSAIDs. Daily intake of selective 
COX-2 inhibitors for two years or more produced a 
significant reduction (60%) in the risk of lung cancer 
(OR=0.40, 95% CI=0.19-0.81).  
Significant risk reductions were also observed for 
the intake of two or more pills per week of regular 
aspirin (OR=0.53, 95% CI= 0.34-0.82), and ibuprofen or 
naproxen (OR=0.40, 95% CI=0.23-0.73). Exposure to 
aspirin, ibuprofen, naproxen or a selective COX-2 in-
hibitor produced a significant reduction in the risk 
(OR=0.47, 95% CI=0.33-0.67). The effect of baby (81 mg) 
aspirin was marginally significant (OR=0.74, P<0.07) 
whereas acetaminophen use did not significantly in-
fluence the relative risk of lung cancer.  
Since smoking is such an overwhelming risk fac-
tor for lung cancer, we also stratified the data on 
smoking status and derived separate estimates by 
smoking status. Estimated risk reductions for the se-
lective COX-2 inhibitors were similar for chronic 
smokers (OR=0.24, 95% CI=0.12-0.45) and nonsmokers 
(OR=0.50, 95% CI= 0.22-1.12). Estimates were also 
similar for women (OR=0.52, 95% CI=0.24-1.13) and 
men (OR=0.26, 95% CI=0.10-0.62) and for subjects who 
reported a past history of arthritis (OR=0.40, 95% 
CI=0.14-1.18) and those who did not (OR=0.38, 95% 
CI=0.17-0.86). Furthermore, odds ratios derived by 
histologic cell type were also similar, e.g., the risk re-
duction for pulmonary adenocarcinoma (OR=0.44, 
95% CI=21=0.93) was similar to that for other 
non-small cell lung cancer (OR=0.33, 95% 
CI=0.15-0.74).   
Table 2. Odds ratios with 95% confidence intervals for lung 
cancer and selective cyclooxygenase-2 (COX-2) inhibitors, and 
over the counter nonsteroidal anti-inflammatory drugs (OTC 
NSAIDS).  
Compound Number 
of Cases 
Number 
of Con-
trols 
Multivariate 
ORd (95% CI) 
None/Infrequent Usea  315 506  1.00 
Any NSAID (aspirin, 
ibuprofen, naproxen, or 
COX-2 inhibitor) 
 
106 
 
320 
 
0.47 
(0.33-0.67) 
 
COX-2 Inhibitorsb 
 
22 
 
71 
 
0.40 
(0.19-0.81) 
OTC NSAIDsc      
Aspirin 60  148  0.53 
(0.34-0.82) 
Ibuprofen/Naproxen 24  101  0.40 
(0.23-0.73) 
Acetaminophen 18  25  1.36 
(0.55-3.37) 
Baby Aspirin  53  133  0.74 
(0.50-1.11) 
a No use of any NSAID or analgesic or infrequent use of no more than 
one pill per week for less than one year;   
b COX-2 inhibitors include celecoxib, rofecoxib, valdecoxib, or 
meloxicam used daily for two years or more. 
c Over the counter (OTC) NSAIDs/analgesics used at least two times 
per week for two years or more.   
d Multivariate odds ratios are adjusted for continuous variables 
(pack years of cigarette smoking, age and body mass) and categori-
cal variables (gender, ethnicity, family history, arthritis and alcohol 
intake). Odds ratios for COX-2 inhibitors are also adjusted for past 
use of NSAIDs. 
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Table 3 presents risk estimates for individual se-
lective COX-2 inhibitors (celecoxib and rofecoxib) plus 
dose-response data for aspirin and ibuprofen. Daily 
use of either 200 mg celecoxib or 25 mg rofecoxib for at 
least two years produced similar risk reductions (72% 
and 45% respectively). The trend data for OTC com-
pounds suggests that 325 mg aspirin or 200 mg ibu-
profen also produced significant risk reductions when 
taken at least every other day for at least five years. 
Table 3. Odds ratios for lung cancer by dose, frequency, and 
duration of exposure to celecoxib, rofecoxib, aspirin, and ibu-
profen.  
Compounda  Dose    Cases    Controls Frequency   
of Use 
 
Multivariate 
ORb  
(95% CI) 
Reference   0  315   506  N/A  1.00 
Celecoxib 200 
mg 
10 36  Daily  0.28 
(0.12-0.67) 
Rofecoxib 25 
mg 
10 35  Daily  0.55 
(0.19-1.56) 
Aspirin 325 
mg 
28 24  1-3  weekly  1.43 
(0.73-2.80) 
   32  124  >3  weekly  0.36 
(0.22-0.58) 
         trend 
(p<0.05) 
Ibuprofen 200 
mg 
8 35  1-3  weekly  0.57 
(0.23-1.39) 
   16  66  >3  weekly  0.36 
(0.19-0.66) 
         trend 
(p<0.01) 
aMinimum duration of exposure: 2 years for celecoxib or rofecoxib, 5 
years for aspirin or ibuprofen.  
bMultivariate odds ratios are adjusted for continuous variables 
(pack-years of cigarette smoking, age and body mass) and categori-
cal variables (gender, ethnicity, family history, arthritis and alcohol 
intake). Odds ratios for COX-2 inhibitors are also adjusted for past 
use of NSAIDs. 
4.  DISCUSSION 
This is the first epidemiologic investigation to 
observe a significant risk reduction in human lung 
cancer due to intake of selective COX-2 inhibitors. 
Standard daily dosages of celecoxib (200 mg) or rofe-
coxib (25 mg) taken for two or more years produced a 
statistically significant risk reduction (60%). Com-
parator NSAIDs with non-selective COX-2 activity 
(325 mg aspirin, 200 mg ibuprofen or 250 mg naproxen) 
also produced significant risk reductions similar in 
magnitude to selective compounds. In contrast, 
acetaminophen, a compound with negligible COX-2 
activity, produced no significant change in lung cancer 
risk.  
Our results are in general agreement with two 
recent meta-analyses showing that regular intake of 
non-selective NSAIDs such as aspirin and ibuprofen 
reduce the risk of lung cancer [3, 4]. These findings 
coupled with existing preclinical, molecular, and epi-
demiologic evidence suggest that aberrant induction of 
COX-2 and up-regulation of the prostaglandin cascade 
play a significant role in human lung carcinogenesis, 
and that blockade of this process has strong potential 
for intervention. 
Mechanism(s) of action 
Two primary genes are responsible for the genetic 
control of cyclooxygenase, a constitutive gene (COX-1) 
and its inducible isoform (COX-2) [23, 24, 25]. Mo-
lecular studies show that the inducible cyclooxy-
genase-2 gene (COX-2) is over-expressed in virtually 
every type of human cancer that has been studied in-
cluding lung cancer [9-11, 26-29]. Metabolism of ara-
chidonic acid via the cyclooxygenase pathway pro-
duces various prostaglandins, prostacyclins and 
thromboxanes, and increased levels have been shown 
in malignant tumors in comparison to benign tumors 
and normal tissues [30-34]. Certain prostaglandins, for 
example PGE2, PGF2-alpha and 6-keto-PGF-1-alpha, 
are upregulated in association with tumor formation 
[35]. Both in vitro and in vivo studies have demon-
strated that inhibition of the cyclooxygenase pathway, 
and particularly COX-2, results in the inhibition of 
tumor growth and development [36-43].  
Inhibition of cyclooxygenase and blockade of the 
prostaglandin cascade may impact upon neoplastic 
growth and development by reducing key features of 
carcinogenesis, vis a vis, mutagenesis, angiogenesis, 
and mitosis, and also by stimulating apoptosis of ma-
lignant cells [44, 45, 46]. It has recently been discovered 
that up-regulation of COX-2 and correlative produc-
tion of prostaglandin E2 (PGE2) effectively and spe-
cifically induces the promoter II region of the cyto-
chrome P-450 gene (CYP-19) which is transcribed and 
translated into aromatase, the chief enzyme in the 
biosynthesis of estrogen [47, 48]. It is well known that 
estrogen has strong proliferative effects and mitogenic 
potential, and procedures which reduce estrogen lev-
els or estrogen activity have been associated with de-
creased risk of breast cancer as well as other malig-
nancies. The COX blocking agents have also been 
found to activate the peroxisome proliferator-activated 
receptors (PPAR), ligands which modulate neoplastic 
transcription in conjunction with upregulation of the 
prostaglandin cascade [49]. Recent investigations of 
human cell lines and tissue samples of adenocarci-
noma of the lung and of a hamster model of 
NNK-induced adenocarcinoma reveal overexpression 
of beta-adrenergic receptors which modulate arachi-
donic acid release and stimulate carcinogenesis [12, 13, 
14, 15]; notably, these effects are blocked by admini-
stration of NSAIDs [12]. These multiple lines of evi-
dence suggest that aberrant induction and upregula-
tion of the prostaglandin cascade play a significant role 
in carcinogenesis, and that blockade of this process has 
strong potential for intervention. 
COX-2 Controversy 
Celecoxib (Celebrex) and rofecoxib (Vioxx) were 
approved for the treatment of arthritis by the FDA in 
1999. In randomized clinical trials, both compounds 
demonstrated better gastrointestinal safety and effi-
cacy profiles than their NSAID predecessors [50-54]. 
Following FDA approval, each of these drugs was 
routinely prescribed to millions of individuals who 
suffered from arthritis and other inflammatory condi-Int. J. Biol. Sci. 2007, 3 
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tions. It was thus unsettling to both patients and pre-
scribing physicians alike when Merck recalled Vioxx 
from the market due to concerns regarding cardio-
vascular outcomes [55]. Subsequently, the cardiovas-
cular safety of all selective COX-2 inhibitors has come 
under scrutiny [56].   
Randomized clinical trials (RCTs) have tradition-
ally been the gold standard for unbiased assessment of 
the risks versus benefits of therapeutic and chemo-
preventive medications. Extraordinary media cover-
age has been given to the two RCTs wherein increases 
were observed in the risk of adverse cardiovascular 
outcomes with long term intake of well-known selec-
tive COX-2-inhibiting agents (rofecoxib and celecoxib) 
[57, 58 59]. Unfortunately, several potential pitfalls in 
these investigations have not been explored. These 
include the following:  
1. Dosages of both rofecoxib (Vioxx) and cele-
coxib (Celebrex) administered in these RCTs were 
above the standard recommended doses (2 and 4 times, 
respectively, the typical dose used in the treatment of 
arthritis). 
2. Only fixed doses were tested without adjust-
ment according to body size as recommended by the 
drug manufacturers. Because the therapeutic window 
of smaller individuals is usually reduced, their dose 
should have been lowered and safety tolerance 
checked by measuring individual blood levels. 
3. Data of both RCTs were examined by “inten-
tion to treat” analysis which assumes that all indi-
viduals who were enrolled for study completed the 
full course of treatment. Since there were substantial 
losses of subjects to follow-up in both RCTs, this 
method may have led to unreliable results pertaining 
to etiologic effects of the compounds. 
4. Cox regression analysis was applied in the 
examination of data; however, the Cox model used 
incorporated only treatment effects without adjust-
ment for individual cardiovascular risk factors. As a 
consequence, results may have been influenced by 
confounding, interaction (effect modification), or both.  
5. Since neither RCT was designed to examine 
cardiovascular outcomes, inclusion of only such out-
comes (as opposed to all adverse events) may have 
compromised probability levels in tests of significance.  
Furthermore, focus on these two studies at the 
exclusion of others has produced misinformation 
about the cardiovascular safety of individual COX-2 
inhibitors. For example, comprehensive meta-analyses 
of randomized clinical trials find no evidence sup-
porting a general “class effect” of selective COX-2 
inhibitors but rather suggest that rofecoxib may in-
crease cardiovascular risk (60, 61, 62, 63, 64), blood 
pressure and renal dysfunction [65] whereas celecoxib 
does not.  
Clearly, future chemopreventive studies should 
attempt to eliminate sources of bias and accurately 
elucidate risk versus benefit of the selective COX-2 
inhibitors. Comparative studies should be designed to 
determine the appropriate dose, duration, side effects, 
and cost-effectiveness of individual compounds. Con-
tinued exploration of selective COX-2 inhibitors 
should be considered a top cancer research priority. 
Our findings of marked decreases in lung cancer risk 
with COX-2 blockade underscores the critical need for 
human clinical investigations of these compounds in 
order to expedite their efficacious application in the 
chemoprevention and therapy of cancer. Furthermore, 
experimental designs of chemopreventive clinical tri-
als should embellish rather than ignore two golden 
rules of medicine: the dose makes the poison and first 
do no harm [66]. 
5.  CONCLUSIONS  
We conducted a case control study to examine the 
effects of selective COX-2 inhibitors against human 
lung cancer. Results are summarized below: 
1. Daily intake of selective COX-2 inhibitors 
produced a significant reduction (60%) in the risk of 
human lung cancer.   
2. Similar risk reductions were observed for indi-
vidual COX-2 inhibitors, celecoxib and rofecoxib. 
3. The observed chemopreventive effects were 
associated with recommended daily doses of celecoxib 
(median dose=200 mg) or rofecoxib (median dose=25 
mg). 
4. Significant risk reductions of similar magni-
tude were observed for over the counter NSAIDs with 
non-selective COX-2 activity, such as regular (325mg) 
aspirin and (200 mg) ibuprofen.  
5. Daily intake of baby (81 mg) aspirin produced a 
marginally significant risk reduction in lung cancer. 
6. Acetaminophen, an analgesic without COX-2 
activity, did not produce a significant change in the 
risk of lung cancer. 
Notably, selective COX-2 inhibitors (celecoxib 
and rofecoxib) were only recently approved for use in 
1999, and rofecoxib (Vioxx) was withdrawn from the 
marketplace in 2004. Nevertheless, even in the short 
window of exposure to these compounds, the selective 
COX-2 inhibitors produced significant reductions in 
the risk of lung cancer. These early results tend to 
substantiate the important role of COX-2 in lung car-
cinogenesis, and reciprocally, the strong potential for 
selective COX-2 blockade in lung cancer chemopre-
vention. Further studies will be required to determine 
the appropriate dose, frequency of intake, duration, 
side effects and cost effectiveness of COX-2 inhibitors 
in the chemoprevention of lung cancer. 
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